Testosterone for gender dysphoria in transgender me

Phase 4

Completed

• Conditions: Transgender health; Gender dysphoria; Depression; Suicide; Metabolic and Endocrine - Other endocrine disorders; Mental Health - Depression; Mental Health - Suicide

• Registration Number: ACTRN12621000716864
• Lead Sponsor: niversity of Melbourne

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2021-06-08
• Study Completion: 2022-10-05
• Last Update Posted: 6 March 2023

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 64

Inclusion Criteria

Transgender men newly commencing testosterone therapy.

Exclusion Criteria

Contraindication to testosterone
Elevated haematocrit at baseline
Previous testosterone treatment
History of major psychiatric disease or psychological condition that may limit understanding and compliance with study requirements
Medications for antiplatelet or anticoagulant therapy

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Symptoms of gender dysphoria, as graded by the Gender Preoccupation and Stability Questionnaire[12 weeks post-enrolment]

Secondary Outcome Measures

Name	Time	Method
Psychological distress, as graded by the Patient Health Questionnaire 9[12 weeks post-enrolment];Suicidality, as graded by the Suicidal Ideation Attributes Scale (SI-DAS)[12 weeks post-enrolment];Quality of life, as graded by the EQ-5D-5L [12 weeks post-enrolment]